A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 3/3/2010

Posted by | 4:32pm on Wednesday, March 3, 2010

:
Welcome to the pharma marketing & social media #socpharm chat. Plse introduce yourself & say why you are interested in this topic. 3/3/2010 19:02

:
I’m working from my iPhone tonight since Twitter suddenly decided to lock me out! So excuse the slowness. #socpharm

:
Hi, Eileen…looking forward to a lively discussion. #socpharm

:
I’m Eileen & work at Siren Interactive focusing on rare disorder therapies. Fascinated to use sm for this. #socpharm

:
@ hi Rob introduce yourself to the lurkers! #socpharm

:
We’ll assume that all tweets within #socpharm are your own & not your employer (unless you specifically declare them)

:
Hi Eileen, what is tonight’s topic? #socpharm

:
Looking at the Eli Lily sponsored depression quizz on @ that only gave a positive dx of depression. How bad is it for Lilly? #socpharm

:
Hi Eileen, John O’Brien here. Pharmacist, health policy professor, & consultant #socpharm

:
I’m Rob and I work in healthcare communications. Social Media is where it’s at! #socpharm

:
Read about it here http://bit.ly/brNxYk #socpharm

:
DA gone wrong will add up until an industry critic, reporter & state legislator go public with all of it at once #socpharm

:
How does something like that depression quizz go so wrong? Who would think that would be a good idea? So bad for WebMd rep too #socpharm

:
@ Because the internet is still the wild west and consumers don’t know that Google targets ads based on their email? #socpharm

:
@ sorry I’m on phone 2night – nightmare! Link is http://bit.ly/brNxXk #socpharm

:
@ The real issue in #fdasm will be one of public health: Do consumers know the difference between ads and advice? #socpharm

:
@ I would venture to say they don’t. But would argue that interest in a condition that leads to Dr Discussions is good #socpharm

:
@ Some consumers are sophisticated, many not. But if an ad takes them to dr to talk still beneficial. #socpharm

:
@ That’s the argument that got DTC approved in 1997. But every “Dr. Sellout” story erodes the argument. #socpharm

:
“Dr Sellout”? Can you clarify? #socpharm

:
A clueless consumer sent to an overwhelmed doctor who doesn’t stay current & evidence-based is a problem #socpharm

:
I prefer to see my physician, Dr. Feelgood… #socpharm

:
@ Agreed! Evidence based is key. Value based purchasing and quality are also key, especially in current environment. #socpharm

:
T2 On the last day for #fdasm comments a few pharmacos submitted. Did u read any at http//fdasm.com/comments? Thoughts? #socpharm

:
@ Agree back! The BEST use of #socpharm will help consumers be responsible for their own health and teach what value means.

:
I thought it was interesting that Lilly recommended global consensus around AEs. #socpharm

:
@ I thought there was a lot of corporate speak and blah blah in the company #fdasm submissions #socpharm

:
@ it’s pharma, isn’t that assumed?!? Did u find any interesting tidbits? I haven’t read them all yet. #socpharm

:
I read the comments as a restating of their missions & what they feel they cant control #socpharm e.g., Lilly’s “cost vs content” argument

:
Merck has a few good points re search and redirects not being transparent. Not an advocate for their proposed Advisory Committe #socpharm

:
@ it’s all about control and what they can’t do, hardly anyone was thing about the patient perspective or outcomes #socpharm

:
@ oops thinking not thing, typo! #socpharm

:
@ perhaps but pharma truly can bring value so the patients will benefit from increased info & support #socpharm

:
@ More likely someone will encourage a 3rd party to be too aggressive and it will taint the whole industry when found #socpharm

:
@ yes but that wasn’t where they were coming from. My concern was that they’re so promotion focused #socpharm

:
@ that is a big concern #socpharm

:
It will, however, be a boom time for novel/rare disease groups and the vendors who help them organize #socpharm

:
Of course they are in the business of selling drugs. Patient benefits are a lovely side benefit. #socpharm

:
Perfect segue to T3: study showed 58% of rare disease pts said health improved due to online community membership. Thoughts? #socpharm

:
To #drjmob point earlier…best use of sm in pharma is disease education. That is less restricted by current regs. #socpharm

:
@ Study link, citations? #socpharm

:
I believe this to be true, especially in rare diseaes. Pts can talk to others about rxs and treatments. #socpharm

:
T3 study from @ & @ http://bit.ly/9jq6wH #socpharm

:
@ makes sense…even weight watchers claims better results through community–not that it’s worked for me ;) #socpharm

:
@: hey Rob, curious why you don’t like Merck’s proposed advisory committee from #fdasm! I think I know, but details? #socpharm

:
@ Thanks. I have much respect for NORD @ #socpharm

:
37% of rare disease pts surveyed unsure if treatment for their condition. Huge opportunity for pharma #socpharm

:
Awareness is a drop in the health belief ocean, especially when the tx are expensive and third-tiered #socpharm

:
@ agree! Survey was only 554 people but for #rarediseases that’s significant. #socpharm

:
I think you guys are almost over, but wanted to say hello! #socpharm

:
@ for me it seems like another layer to wade thru. Better approach is to get foundation reasoning and to let things evolve #socpharm

:
The best rare disease #socpharm sites will help patients change beliefs & behaviors, AND overcome financial barriers (e.g., copay assist)

:
YES RT @ best rare disease #socpharm sites will help patients change beliefs & behaviors AND overcome financial barriers (copay assist

:
@ Read through 70% of them… still processing, to be honest. Some are making some ludicrous claims with no support. #socpharm

:
Thanks everyone for sharing your insights tonight. Have a great week – see you next Wed at 8 pm est #socpharm

:
@ Thanks as always #socpharm contributors and lurkers!

:
PhRMA proper’s #FDASM comments were really good. Pragmatic, forward thinking, and responsible #socpharm 3/3/2010 20:05

:
@ I completely agree. Huge holdup during med/legal review process of #newmedia channels and engagement implications #socpharm 3/3/2010 21:02

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com